FiercePharma19h
UCB’s Bimzelx outpacing AbbVie’s Rinvoq, Skyrizi on awareness early in psoriatic arthritis launch: survey
UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...
InnovationRx: Federal Judges Halt Trump’s Cuts To NIH Research Payments
In this week's InnovationRx newsletter, federal judges halt Trump's cuts to NIH research payments, rural hospitals' ongoing ...
ENDPOINTS NEWS3d
No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos
Novartis acquires Anthos' abelacimab for $925M upfront and up to $3.1B total, marking CEO Bill Meury's second major exit and ...
Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion
The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...
FierceBiotech3d
Novartis inks $925M Anthos takeover to buy back phase 3 clot-busting candidate
Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...